INDIVIDUAL TEST 247
PLA2R Antibodies ELISA (IgG)
Indication
Suspicion of primary membranous nephropathy (PMN).
Sample material
Serum
- Minim. volume: 0,5 mL
Transport
Within Sweden
- room temperature
International
- cold
Method
ELISA
Reference interval
<14 RU/mL negative
Result
Results are reported as negative, borderline, or positive with a concentration (RU/mL).
Interpretation
Antibodies against PLA2R are a strong marker for primary membrane nephropathy (PMN). Antibodies against PLA2R lead to complement-activating immune complexes deposited on the basal membrane in glomeruli, with tissue damage and proteinuria as a consequence.
Antibodies against PLA2R occur in serum in 75% of the PMN cases. The concentration of antibodies is associated with disease development, and their concentration determination by ELISA (RU/ml) can be used to follow the treatment effect.
In case of negative results, it is recommended to supplement with testing for antibodies against Thrombospondin Type 1 Domain Containing 7A (THSD7A), which occurs in approximately 10% of anti-PLA2R negative PMN. The simultaneous presence of antibodies against PLA2R and THSD7A is very unusual.References
- Beck LH Jr et al. N Engl J Med. 2009. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. PMID: 19571279
- Ronco P, Debiec H. J Am Soc Nephrol. 2010. Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy. PMID: 20185638
- Gödel M et al. N Engl J Med. 2015. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. PMID: 25760365
- Tomas NM et al. N Engl J Med. 2014. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. PMID: 25394321
- Ronco P, Debiec H. Lancet. 2015. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. PMID: 26090644
- Larsen CP et al. Mod Pathol. 2016. THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity. PMID: 26847174
Last updated: 2024-06-26
Can't find what you're looking for? We are here to help
ENSKILD ANALYS 247
PLA2R-antikroppar ELISA (IgG)
Indikation
Misstanke om primär membranös nefropati (PMN).
Provmaterial
Serum
- Minim. volym: 0,5 mL
Transport
Inom Sverige
- rumstemperatur
Internationellt
- kylt
Metod
ELISA
Referensintervall
< 14 RU/mL negativt
Resultat
Resultat anges som negativt, gränsvärde eller positivt med koncentration (RU/mL).
Tolkning
Antikroppar mot PLA2R är en stark markör för primär membranös nefropati (PMN) och leder till komplementaktiverande immunkomplex som deponeras på basalmembran i glomeruli med vävnadsskada och proteinuri som följd.
Antikroppar mot PLA2R förekommer i serum hos 75% av patienter med primär membranös nefropati. Koncentrationen av antikropparna är kopplad till sjukdomsaktivitet. Koncentration bestämning (RU/ml) med ELISA kan användas för uppföljning av behandlingseffekt.
Vid negativt resultat rekommenderas komplettering med analys av antikroppar mot Thrombospondin Type 1 Domain Containing 7A (anti-THSD7A) som förekommer i ca 10% av anti- PLA2R negativ PMN. Samtidig förekomst av antikroppar mot PLA2R och THSD7A är mycket ovanligt.
Referenser
- Beck LH Jr et al. N Engl J Med. 2009. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. PMID: 19571279
- Ronco P, Debiec H. J Am Soc Nephrol. 2010. Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy. PMID: 20185638
- Gödel M et al. N Engl J Med. 2015. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. PMID: 25760365
- Tomas NM et al. N Engl J Med. 2014. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. PMID: 25394321
- Ronco P, Debiec H. Lancet. 2015. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. PMID: 26090644
- Larsen CP et al. Mod Pathol. 2016. THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity. PMID: 26847174
Senast uppdaterat: 2024-06-26